OBJECTIVES:  A real-life cost-effectiveness evaluation in 2008 showed that medication costs of budesonide/formoterol for maintenance and reliever therapy (MART) via dry powder inhaler (DPI) was significantly lower than medication costs associated with fixed-dose combination (FDC) of budesonide/formoterol in conventional way (FDC of ICS/LABA + additional reliever) and free adjustable combination (FAC) of budesonide and formoterol, with at least equal effectiveness. In 2014 the Dental and Pharmaceutical Benefits Agency (TLV) in Sweden assessed all inhaled corticosteroids (ICS), long-acting beta-2-agonists (LABA) and their FDCs where the outcomes suggested equal effectiveness across treatment strategies and a pricing corridor was implemented. The objective is to update the medication costs for a real-life cost-effectiveness analysis of treating asthma in Swedish primary care and to evaluate the medication costs in Denmark. METHODS: Medication costs from 2006 included all pharmaceuticals in the analysis which were inflated to 2015 price levels and then compared to today’s actual prices of medications used in the FAC arm (Pulmicort® Turbuhaler® & Oxis® Turbuhaler®, plus terbutaline as needed), FDC arm (Bufomix® Easyhaler® plus terbutaline as needed) and the budesonide/formoterol MART arm (DuoResp®  Spiromax®). The same analysis was conducted for both Sweden and Denmark. RESULTS: The medication costs in the budesonide/formoterol MART arm is less costly when considering DuoResp® Spiromax®, SEK 3336.4 (SEK 4710.9) per patient and year compared to SEK 4163 (SEK 6157) in the FDC arm and SEK 7498.5 (SEK 5637.6) FAC arm. In Denmark the same trend is visible where the MART arm was DK 4183.5 (DK 4573) compared to DK 4579 (DK 5905.2) in the conventional FDC arm and 4510.4 (DK 4511.7) in the FAC arm. CONCLUSIONS:  Compared to conventional treatment arm (FDC + reliever) and free adjustable combination (FAC) arm, DuoResp® Spiromax® with MART usage has the potential to be cost saving option with at least equivalent efficacy.